Table 1. Study characteristics, by treatment group.
| Study | Country | Patients
included (N) |
Median/
mean age (years) |
Female
(%) |
VF definition | Study
type |
Eligibility criteria | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Previous
VF allowed |
Previous
resistances allowed |
Months
of stable ART |
Months
with HIV VL<50 |
CD4
nadir (cells/ µl) |
Other | |||||||
| DTG-Mono | ||||||||||||
| Katlama
et al.
JAC 2016 |
F | 28 | 48 | 46.4 | 2× ≥ 50 cp/ml or
1× > 200 cp/ml |
O | Yes | - | - | ≥ 12 | - | - |
| Wijting
et al.
Lancet HIV |
NL | 96 | 45.5 | 8.5 | 2× ≥ 200 cp/ml | I | No | No | - | ≥ 6 | >200 | VL zenith <100.000 |
| Gubavu
et al.
JAC 2016 |
F | 21 | 47 | 38 | 2× ≥ 50 cp/ml | O | Yes | - | - | - | - | - |
| Oldenbüttel
et al.
AVT 2016 |
D | 31 | 44.5 | 32 | 2× ≥ 20 cp/ml | O | Yes | Not to InSTI | - | ≥ 6 | - | no AIDS history |
| Rokx
et al.
JAC 2016 |
NL | 5 | 63 | 0 | 2× ≥ 50 cp/ml | I | Yes | - | - | ≥ 12 | - | - |
| Rojas
et al.
JAC 2016 |
E | 31 | 56 | 55 | 2× ≥ 37 cp/ml | O | Yes | - | - | - | - | - |
| Lecompte
et al.
IAS 2017 |
CH | 8 | 44.5 | 28.5 | 1× ≥ 200cp/ml | I | No | No | ≥ 24 | - | - | - |
| Blanco
et al.
JAC 2018 |
E | 31 | 47 | 10 | 2× ≥ 50 cp/ml or
1× > 1000 cp/ml |
I | Yes | - | - | ≥ 12 | >200 | - |
| DTG-3TC | ||||||||||||
| Borghetti
et al.
JAC 2016 |
I | 36 | 53 | 19.4 | 2× ≥ 50 cp/ml | O | Yes | - | - | - | - | |
| Maggiolo
et al.
BMC ID 2017 |
I | 94 | 52 | 32.3 | 2× ≥ 50 cp/ml | O | Yes | Not to 3TC
or InSTI |
> 6 | ≥ 6 | - | - |
| Joly
et al.
CROI 2017 |
F | 104 | 45 | 14.4 | 2× ≥ 50 cp/ml | I | No | No | - | ≥ 24 | >200 | no HIV encephalitis £ |
| Reynes
et al.
HIV Glasgow 2016 |
F | 27 | 59 | 25.9 | 2× ≥ 50 cp/ml | O | Yes | Not to InSTI | > 12 | - | - | - |
| Blanco
et al.
JAC 2018 |
E | 29 | 44 | 21 | I | Yes | - | - | ≥ 12 | >200 | - | |
| Maggiolo
et al.
EACS 2017 |
I | 203 | 52 | 24.6 | - | O | Yes | No M184V | - | ≥ 6 | - | - |
| Taiwo
et al.
CID 2017 |
US | 44 | 46 | 17 | 2× ≥ 50 cp/ml | I | No | No | ≥ 12 | ≥ 12 | ||
| DTG-RPV | ||||||||||||
| Llibre
et al.
Lancet 2018 |
Multi-
country |
513 | 43 | 23 | 1× ≥ 50 cp/ml | I | No | - | > 6 | ≥ 12 | - | - |
| Gantner
et al.
HIV Med 2017 |
F | 116 | 55 | 44 | 2× ≥ 50 cp/ml or
1× ≥ 1,000 cp/ml |
O | Yes | - | - | - | - | - |
| Bonijoly
et al.
EACS 2017 |
F | 268 | 55 | 44 | 2× ≥ 50 cp/ml | O | Yes | - | - | ≥ 6 | - | On ART for ≥ 12
months |
| Revuelta
et al.
Ann pharmacol 2018 |
E | 32 | 49 | 37 | 2× ≥ 50 cp/ml | O | Yes | Not to InSTI
or RPV |
- | - | - | - |
| DTG-ATV | ||||||||||||
| Riva
et al.
HIV Glasgow 2016 |
I | 61 | 52.1 | 39 | - | O | - | - | - | - | - | - |
| Castagna
et al.
EACS 2017 |
I | 116 | 53 | 13 | 2× ≥ 50 cp/ml | O | - | - | - | ≥ 12 | - | - |
| DTG-DRV | ||||||||||||
| Navarro
et al.
EACS 2017 |
E | 27 | 52 | 30 | 2× ≥ 50 cp/ml | O | Yes | Only to one
ART class |
- | ≥ 6 | - | - |
Abbreviations: VF: virologic failure, ART: antiretroviral therapy, DTG: dolutegravir, 3TC: lamivudine, FTC: emtricitabine, RPV: rilpivirine, ATV: atazanavir, InSTI: integrase stand transfert inhibitor, F: France, NL: The Netherlands, D: Germany, E: Spain, CH: Switzerland, I: Italy, USA: United States of America, O: observational study; I: interventional study
£: no abnormal standard biological parameter